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Abstract
The study investigated the role of protein kinase C (PKC) in the modulation of agonist-induced Ca2-dependent anion
secretion by pancreatic duct cells. The short-circuit current (ISC) technique was used to examine the effect of PKC activation
and inhibition on subsequent ATP, angiotensin II and ionomycin-activated anion secretion by normal (CAPAN-1) and cystic
fibrosis (CFPAC-1) pancreatic duct cells. The ISC responses induced by the Ca2-mobilizing agents, which had been
previously shown to be attributed to anion secretion, were enhanced in both CAPAN-1 and CFPAC-1 cells by PKC
inhibitors, staurosporine, calphostin C or chelerythrine. On the contrary, a PKC activator, phorbol 12-myristate 13-acetate
(PMA), was found to suppress the agonist-induced ISC in CFPAC-1 cells and the ionomycin-induced ISC in CAPAN-1 cells.
An inactive form of PMA, 4KD-phorbol 12,13-didecanote (4KD), was found to exert insignificant effect on the agonist-
induced ISC, indicating a specific effect of PMA. Our data suggest a role of PKC in modulating agonist-induced Ca2-
dependent anion secretion by pancreatic duct cells. Therapeutic strategy to augment Ca2-activated anion secretion by cystic
fibrosis pancreatic duct cells may be achieved by inhibition or down-regulation of PKC. ß 1999 Elsevier Science B.V. All
rights reserved.
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1. Introduction
The cAMP-dependent Cl3 secretion is defective in
cystic ¢brosis (CF), a common lethal genetic disease
a¡ecting 1 in 2500 of the Caucasian population [1].
Impaired bicarbonate secretion, as well as Cl3 secre-
tion, underlies the defective £uid secretory response
in the cystic ¢brosis pancreas [2,3]. Obstruction of
ducts by inspissated secretion followed by tissue de-
struction appears to be the cause of some diseases of
the pancreas, including endocrine pancreatic failure
and diabetes. Alternative activation pathways of Cl3
secretion have been proposed as the basis for thera-
peutic intervention, and it has been demonstrated
that the Ca2-dependent Cl3 secretion is intact in a
number of CF tissues, including the pancreatic duct
cells [4,5]. Previous studies [6,7] have also shown that
Ca2-mobilizing agents, ATP, AII as well as the
Ca2 ionophore, ionomycin, stimulate anion secre-
tion across CFPAC-1 cells, a human CF pancreatic
duct cell line that displays the CF defect ^ lacking
cAMP-dependent Cl3 channel activation [8].
Protein kinase C (PKC) has been implicated in
regulating Cl3 secretion in a number of epithelia
[9^16]. However, the role of PKC in modulating epi-
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thelial functions or responses has been controversial
largely due to its diverse e¡ects on numerous regu-
latory pathways. While PKC is believed to play a
role in regulating cystic ¢brosis transmembrane con-
ductance regulator [15,17^20], which has been shown
to be a cAMP-activated Cl3 channel [21], the e¡ects
of PKC on Ca2-activated Cl3 secretion [22^26], as
well as volume-sensitive Cl3 current [27,28], have
been noted. The existence of di¡erent regulatory
pathways in epithelial cells presents a di⁄culty in
elucidating the precise role of PKC in modulating
individual regulatory pathway.
The present study has made use of a cell line dis-
playing the CF phenotype, with defective cAMP-
regulated but intact Ca2-dependent secretory re-
sponse [8], to investigate the role of PKC in modu-
lating Ca2-dependent pancreatic ductal secretion.
We examined the e¡ect of PKC on agonist-induced
Ca2-dependent anion secretion by CFPAC-1 cells
and compared it to that by a normal pancreatic
cell line CAPAN-1 which has been shown to con-
serve most of the properties of ductal epithelial cells
[29,30] and possess apical cAMP-dependent Cl3
channels which are crucial to pancreatic ductal
HCO33 secretion [31,32]. Pancreatic cells were grown
on semi-permeable membranes and mounted in Us-
sing chambers. Electrogenic anion secretion was re-
£ected by the short-circuit current (ISC) measured.
Our results indicated that PKC attenuates Ca2-de-
pendent agonist-induced ISC in both normal and CF
cells and that augmentation of the agonist-induced
ISC in CF cells by PKC inhibitors may have thera-
peutic potentials.
2. Materials and methods
2.1. Materials
Hank’s balanced salt solution (HBSS) was pur-
chased from Sigma (St. Louis, MO, USA). Iscove’s
modi¢ed Dulbecco’s medium, RPMI 1640 medium
and fetal bovine serum (FBS), trypsin-EDTA were
supplied by Gibco (New York, USA).
The following drugs were supplied by Sigma (St.
Louis, MO, USA): N-methyl-D-glucamine (NMDG),
calcium gluconate, N-2-hydroxethylpiperazine-NP-2-
ethanesulfonic acid (HEPES), staurosporine, cal-
phostin C, adenosine 5P-triphosphate (ATP), 4KD-
phorbol 12,13-didecanote (4KD), ionomycin, Hank’s
balanced salt solution (HBSS), sodium pyruvate and
trypsin. Chelerythrine was purchased from Calbio-
chem Novabiochem (California, USA). Phorbol 12-
myrisate 13-acetate (PMA) was from RBI (Natick,
MA, USA).
2.2. Cell culture
Normal and CF pancreatic duct cell lines, CA-
PAN-1 and CFPAC-1, were purchased from Ameri-
can Type Culture Collection (Maryland, USA). Cul-
ture procedure for CFPAC-1 cells, grown in Iscove’s
modi¢ed Dulbecco’s medium supplemented with 10%
FBS, has been described previously [6]. CAPAN-1
cells were grown in RPMI 1640 medium with 15%
FBS. When cells were disassembled from the culture
£ask, 0.25% trypsin-EDTA was added with extra
care to avoid striking on cell layer directly. Quickly
afterwards, less than 1 min, most of the trypsin was
removed leaving about 0.5 ml in the £ask which was
then incubated for 2^3 min. Cells were then resus-
pended in serum-containing medium with gentle pi-
petting of the cells to break up the cell aggregations.
The suspension was then transferred into a centrifuge
tube for spinning at 800Ug for 5 min to remove any
trypsin left. Supernatant was discarded and the cells
were resuspended with desirable volume of medium
to make up to a ¢nal cell concentration of 1.5U106/
ml. A volume of 0.25 ml of the cell suspension was
then plated onto each permeable support (area of
0.45 cm2) £oating on culture medium and incubated
at 37‡C with 5% CO2/95% O2 for 4^5 days before ISC
experiments.
2.3. Short-circuit current measurement
The basic principles of the short-circuit current
experiments performed in the present study was the
same as previously described [33]. Monolayers grown
on permeable supports were clamped vertically be-
tween two halves of the Ussing chamber and bathed
in Krebs^Henseleit (K^H) solutions with following
composition (mM): NaCl, 117; KCl, 4.7; MgSO4,
1.2; KH2PO4, 1.2; NaHCO3, 24.8; CaCl2, 2.56; glu-
cose, 11.1; with an osmolarity of 285 mOsm gassed
with 95% O2 and 5% CO2.
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All the electrodes were connected to the voltage^
current clamp ampli¢er (DVC-1000, World Precision
Instrument, Sarasota, USA). The signal output from
the ampli¢er was the ISC measured and was recorded
on-line by the use of chart-recorder (Kipp and Zo-
nen, Delft, Netherlands). A 0.1-mV voltage pulse was
applied intermittently across the epithelium and the
transepithelial conductance was calculated from the
corresponding current changes.
PMA, ionomycin and staurosporine, chelerythrine
and 4KD were dissolved in DMSO. To eliminate the
solvent e¡ect, control experiments were performed
with equal amounts of DMSO added.
2.4. Statistical analysis
Results are expressed as mean þ S.E.M. Compari-
sons between groups of data were carried out using
Student’s unpaired t-test. A P-value less than 0.05
was considered to be statistically signi¢cant.
3. Results
3.1. E¡ects of PKC activator and inhibitor on
agonist-induced ISC in CF cells
AII (5 WM), one of the Ca2-mobilizing agonists,
induced a transient rise in ISC in CFPAC-1 cells (Fig.
1, upper panel). Its stimulating e¡ect was suppressed
by a PKC activator, PMA (100 nM), from the con-
trol value of 2.5 þ 0.3 to 0.6 þ 0.1 WA/cm2 (P6 0.01)
with a total reduction of 76.5% (n = 8, Fig. 1, upper
panel). On the contrary, the AII-induced ISC was
increased by a PKC inhibitor, staurosporine (10
WM), from 2.5 þ 0.3 to 5.4 þ 0.4 WA/cm2 (P6 0.01)
with a total increase of 116.9% (n = 7, Fig. 1, upper
panel). To eliminate the possibility of non-speci¢c
e¡ect of staurosporine, the e¡ect of another potent
PKC inhibitor, calphostin C [34], was also examined.
Similar enhancing e¡ect on the AII-induced ISC was
observed (not shown), further indicating the involve-
ment of PKC. Fig. 1 (lower panel) shows the sum-
mary of the e¡ects of PMA and staurosporine.
Similar to its inhibitory e¡ect on the AII-induced
ISC, PMA was also found to suppress the ATP-in-
duced ISC in CFPAC-1 cells, from 9.2 þ 0.9 (n = 6) to
2.7 þ 0.5 WA/cm2 (n = 4, P6 0.01) with a total reduc-
tion of 71% (Fig. 2). Calphostin C was found to
potentiate the ATP-induced ISC by 64%, from
9.2 þ 0.9 to 15.1 þ 1.2 WA/cm2 (n = 4, P6 0.01, Fig.
2). A similar potentiating e¡ect on the ATP-induced
ISC with a 56% increase was also observed for chel-
erythrine, another potent and speci¢c PKC inhibitor
[35] as shown in Fig. 3.
Fig. 1. E¡ect of PKC inhibitor and activator on the angiotensin
II-stimulated ISC in CFPAC-1 cells. Upper panel : ISC response
to AII (5 WM) in control (a), staurosporine (10 WM)-treated (b)
and PMA (0.1 WM)-treated cells (c). Staurosporine and PMA
were added 5 min prior to addition of AII (the same for other
¢gures). Lower panel: summary of corresponding results. Staur-
osporine and PMA are PKC inhibitor and activator, respec-
tively. Potentiating e¡ect was observed with staurosporine while
inhibitory e¡ect with PMA. Each P-value was obtained when
compared to the control. Number of experiments for each col-
umn ranges from ¢ve to eight.
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To con¢rm a role of PKC in modulating the Ca2-
dependent anion secretion, the e¡ects of PMA and
staurosporine on the ISC induced by a Ca2 iono-
phore, ionomycin (10 WM), were also examined. In
contrast to AII and ATP, ionomycin induced a bi-
phasic ISC response with a transient increase followed
by a more sustained increase (Fig. 4). PMA was
found to suppress the ionomycin-induced ISC by
91%, from 14.2 þ 1.3 to 1.3 þ 0.4 (n = 7, P6 0.01,
Fig. 4), while staurosporine enhanced it by 83%,
from 13.2 þ 0.7 (n = 6) to 24.1 þ 2.1 WA/cm2 (n = 4,
P6 0.01, Fig. 5). The speci¢city of PMA was tested
by examining the e¡ect of its inactive analog, 4KD (1
WM), on the ionomycin-induced ISC. As shown in
Fig. 6, 4KD exerted insigni¢cant e¡ect on the iono-
mycin-induced ISC, excluding any non-speci¢c e¡ect
of PMA.
Fig. 2. E¡ect of PKC inhibitor and activator on the ATP-
stimulated ISC in CFPAC-1 cells. Upper panel : ISC response to
ATP (10 WM) in control (a), calphostin C (10 nM)-treated (b)
and PMA (0.1 WM)-treated cells (c). Lower panel: summary of
corresponding results. Calphostin C is another PKC inhibitor.
Number of experiments ranges from four to six.
Fig. 3. E¡ect of chelerythrine on the ATP-stimulated ISC in
CFPAC-1 cells. Upper panel: ISC response to ATP (10 WM) in
control (a) and chelerythrine (10 nM)-treated cells (b). Lower
panel : summary of corresponding results. Chelerythrine is a
newly developed speci¢c inhibitor of PKC. The potentiation of
ATP-activated ISC by chelerythrine mimicked the response in
the presence of staurosporine or calphostin C, suggesting that
inhibition of PKC indeed enhances Ca2-activated anion secre-
tion. Data were obtained from six to eight individual experi-
ments.
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3.2. E¡ects of PKC activator and inhibitor on
agonist-induced ISC in CAPAN-1 cells
The e¡ects of PMA and staurosporine on agonist-
induced ISC were also examined in normal pancreatic
duct cells, CAPAN-1. AII was found to be ine¡ective
in eliciting any ISC response in these cells and, there-
fore, we were unable to assess the e¡ect of PKC on
this agonist-induced ISC. On the contrary, ATP eli-
cited a ISC response in CAPAN-1 cells similar to that
observed in CFPAC-1 cells in that they both were
transient in nature (Fig. 7, upper panel). However,
the time for the ATP-activated current to return to
the basal level in CAPAN-1 cells was signi¢cantly
longer. An averaged magnitude of 14.2 þ 1.0 WA/
cm2 (n = 9) was observed for the ATP-induced ISC
in CAPAN-1 cells, which could be increased by
staurosporine to 18.0 þ 2.0 WA/cm32 (n = 4,
P6 0.01, Fig. 7, lower panel) with a total increase
of 27% (n = 4). However, the e¡ect of PMA on the
ATP-induced ISC was found to be insigni¢cant in
CAPAN-1 cells (Fig. 7).
Fig. 4. E¡ect of PKC activator on the ionomycin-stimulated
ISC in CFPAC-1 cells. Upper panel : ISC response to the Ca2
ionophore, ionomycin (1 WM, n = 7) in control (a) and PMA
(0.1 WM, n = 9)-treated cells (b). Lower panel : summary of cor-
responding results.
Fig. 5. E¡ect of PKC inhibitor on the ionomycin-stimulated ISC
in CFPAC-1 cells. ISC response to the Ca2 ionophore, ionomy-
cin (1 WM) in control (a) and staurosporine (10 WM)-treated
cells (b).
Fig. 6. Demonstration of PKC involvement in CFPAC-1 cells.
ISC response to the Ca2 ionophore, ionomycin (1 WM, n = 4) in
control (a) and 4KD (1 WM, n = 7)-treated cells (b). 4KD is an
inactive structural analog of PMA. The ine¡ectiveness of 4KD
on the ionomycin-activated ISC suggests that the e¡ect of PMA
is speci¢cally on PKC.
BBAMEM 77571 2-4-99
H.S. Cheng et al. / Biochimica et Biophysica Acta 1418 (1999) 31^38 35
In contrast to the ionomycin-induced biphasic re-
sponse observed in CFPAC-1 cells, the ionomycin-
induced ISC response in CAPAN-1 cells was transient
with a time course similar to that elicited by ATP in
CAPAN-1 cells (Fig. 8, upper panel). The ionomy-
cin-induced ISC in CAPAN-1 cells was enhanced by
staurosporine, from 16.8 þ 2.3 (n = 6) to 25.8 þ 1.1
WA/cm2 (n = 7, P6 0.01) with an increase of 54%,
but suppressed by PMA to 10.6 þ 1.9 WA/cm2
(n = 7, Fig. 8) with a 37% reduction.
4. Discussion
As described in our previous studies [6,36], both
CFPAC-1 and CAPAN-1 cells exhibit a very small
basal current which was not altered signi¢cantly by
di¡erent agents examined. Therefore, the present
study focused on the agonist-induced ISC. The e¡ect
of AII, ATP as well as ionomycin on anion secretion
by CFPAC-1 cells has been studied previously and
the involvement of Ca2-dependent mechanism in
these agonist-induced responses demonstrated [6,7].
Fig. 7. E¡ect of PKC inhibitor and activator on the ATP-
stimulated ISC in normal pancreatic duct CAPAN-1 cells.
Upper panel: ISC response to ATP (10 WM, n = 6) in control
(a), staurosporine (20 WM, n = 7)-treated (b) and PMA (0.1 WM,
n = 7)-treated cells (c). Lower panel : summary of corresponding
results.
Fig. 8. E¡ect of PKC inhibitor and activator on the ionomycin-
stimulated ISC in normal pancreatic duct CAPAN-1 cells.
Upper panel: ISC response to the Ca2 ionophore, ionomycin
(1 WM, n = 9) in control (a), staurosporine (20 WM, n = 4)-
treated (b) and PMA (0.1 WM, n = 7)-treated cells (c). Lower
panel : summary of corresponding results.
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The present study further indicates the presence a
Ca2-dependent pathway in both normal and CF
pancreatic cells; however, the agonist-induced ISC
responses in these two cell lines were di¡erent in a
number of aspects. First, the ATP-induced ISC re-
sponse in CAPAN-1 cells lasted signi¢cantly longer
than that observed in CF cells. Secondly, the iono-
mycin-induced ISC response in CF cells was biphasic,
while only the transient response was observed in
CAPAN-1 cells. Finally, the AII-induced response
was only observed in CF but not CAPAN-1 cells.
However, it is di⁄cult to assess whether these di¡er-
ences truly re£ect the di¡erences between normal and
CF pancreatic cells. It is possible that the Ca2-de-
pendent machinery, e.g. receptors, intracellular Ca2
pools, in these cell lines may be altered to di¡erent
extents through the process of transformation.
Despite the apparent di¡erences in the Ca2-de-
pendent responses in the two cell lines, a role of
PKC in modulating these responses has been demon-
strated in the present study. It is shown that PKC
activator, PMA, exerts an inhibitory e¡ect on these
agonist-induced ISC responses in CFPAC-1 cells. On
the other hand, inhibitor of PKC, staurosporine, en-
hances the ISC responses. The involvement of PKC in
modulating agonist-induced ISC is indicated by the
observations that the inhibitory e¡ect of PMA on
the agonist-induced ISC was not observed using an
inactive analog of PMA, 4KD, excluding the non-
speci¢c action of PMA. The enhancing e¡ect of
staurosporine was also mimicked by speci¢c PKC
inhibitors, calphostin C and chelerythrine, further
indicating the involvement of PKC. Since the
cAMP-dependent pathway is defective in CFPAC-1
cells, a role of PKC in modulating the Ca2-activated
anion secretion is thus clearly demonstrated. Interest-
ingly, similar inhibitory and enhancing e¡ect on the
ionomycin-induced ISC was also observed with PKC
activator and inhibitor, respectively, in CAPAN-1
cells which possess both the cAMP and Ca2-de-
pendent pathways. These results suggest an inhibi-
tory role of PKC in Ca2-dependent pancreatic duc-
tal secretion. PKC could attenuate the Ca2-
activated ductal secretion and thereby serve as a
turn-o¡ mechanism. This may be achieved by mod-
ulating intracellular Ca2 store [37] or inactivating
the Ca2-activated K channels [38] on which Cl3
secretion largely depends. In contrast to the previ-
ously observed defective regulation of Cl3 secretion
by PKC in CF cells [10,13,14], the modulation of
Ca2-dependent anion secretion by PKC appears to
operate normally in CF pancreatic duct cells.
The presently observed modulatory e¡ect of PKC
on AII and ATP-stimulated anion secretion may be
of physiological signi¢cance since these agonists have
been implicated in the regulation of pancreatic ductal
secretion. Several key components of the renin^an-
giotensin system (RAS) has been demonstrated in the
canine pancreas [39]. Immunohistochemical localiza-
tion and distribution of AII as well as its receptors in
the pancreas of rodents have been reported [40,41].
Our previous studies have also demonstrated the
presence of AII receptor subtypes as well as the e¡ect
of AII on exocrine secretion in CFPAC-1 cells [7].
Taken together, pancreatic ductal secretion may be
regulated by a local tissue RAS. On the other hand,
release of ATP and/or ADP to activate P2 purino-
ceptors has been implicated in pancreatic islets to
increase the magnitude of insulin response to glucose
stimulation [42]. It is possible that ATP released by
the acinar cells may also in£uence ductal cell func-
tion. A recently elucidated autocrine mechanism of
ATP in regulating anion secretion in numerous epi-
thelial tissues [43] further supports a role of ATP in
the regulation of pancreatic ductal secretion [6]. The
fact that AII and ATP-stimulated anion secretion are
modulated by PKC suggests that PKC may be im-
portant in the ¢ne-tuning of Ca2-dependent pancre-
atic ductal secretion. The potentiating e¡ect exerted
by PKC inhibitors on the agonist-induced anion se-
cretion suggests that PKC may be tonically activated
in the duct cells or that it may be partially activated
by AII and ATP, most likely via a Ca2-dependent
mechanism. The augmentation of the Ca2-depend-
ent anion secretion in CF cells by inhibition of PKC
may have therapeutic implication since the Ca2-de-
pendent pathway has been proposed as an alternative
pathway for circumventing the defective cAMP-de-
pendent anion secretion in CF cells. A recent clinical
trial on CF patients using Ca2 mobilizing agent,
uridine 5P-triphosphate, has been conducted and
shown to be e¡ective [44].
In summary, the present study has demonstrated a
role of PKC in modulating the Ca2-dependent
anion secretion in pancreatic duct cells. Augmenta-
tion of anion secretion in CF cells could be achieved
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by inhibition or down-regulation of PKC. The sig-
naling mechanism involved in mediating the e¡ect of
PKC on Ca2-dependent anion secretion is currently
under investigation.
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